The Continental landscape presents a shifting evolution in the view of psychedelics. Long stigmatized, these substances are now gain traction for their potential therapeutic applications. From Switzerland, where clinical trials are in progress, to the Italy, where awareness is expanding, Europe plays a leading role in this re-evaluation of copyrigh